

Abteilungsbesprechung Juli 2023:

06.07.2023:

Klinischer Teil:

Dissertationspräsentation P. Harder

DOI: entfällt

Wissenschaftlicher Teil:

Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment

DOI: 10.1126/sciadv.abi9119

Referent: Justus Ramtke

13.07.2023:

Klinischer Teil:

Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness

DOI: Blood. 2020;136(17):1903-1906

Referent: S. Freitag

Wissenschaftlicher Teil:

High-parameter analysis using full spectrum flow cytometry: Inside COVID-19

Ergebnisse eigene Studie

Referentin: Wendy Bergmann

20.07.2023:

Klinischer Teil:

Real-world use of defibrotide for veno-occlusive disease/ sinusoidal obstruction syndrome: the DEFIFrance Registry Study

DOI: 58:367–376;

Referentin: F. Brückner

<https://doi.org/10.1038/s41409-022->

Wissenschaftlicher Teil:

Establishment of patient-derived organoid models of lower-grade glioma, Neuro-

doi.org/10.1093/neuonc/noab273

Referent: Philipp Kaps

27.07.2023:

Klinischer Teil:

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim

analysis of a multicentre, open-label, randomised, phase 3 trial

DOI: [https://doi.org/10.1016/S1470-2045\(23\)00144-4](https://doi.org/10.1016/S1470-2045(23)00144-4) Referent: A. Seehausen

Wissenschaftlicher Teil:

Tavakoli, S., Nabizadeh, M., Makhamreh, A. et al. Semi-quantitative detection of
doi.org/10.1038/s41467-023-35858-w Referentin: Sophia Wendt

